Skip to main content
. 2014 Sep 29;15(10):17577–17600. doi: 10.3390/ijms151017577

Figure 1.

Figure 1

(a) Periodic Acid-Schiff staining for goblet cells from representative sections of lobar bronchi or daughter generation airway in mice from air-exposed (I), OVA-exposed (II), OVA-exposed Dex-treated (III), OVA-exposed Dex NP (IV), and OVA-exposed NP (V) treated mice [11]; (b) Total lung compliance in mice exposed to either filtered air or 2 weeks of OVA alone [11]; (c) Total respiratory system resistance in Balb/c mice exposed to either filtered air or 1 week of OVA alone (treatment with either Dex or itsnanoparticle drug vehicle (NP) independently attenuated Rrs and AHR (*, ** p < 0.0001) down to air control levels at the highest dose of methacholine) [11]; (d) Plasma profile of following the nebulization of drug-loaded PLG-NP, and oral administration of rifampicin [13]; (e) Plasma profile of following the nebulization of drug-loaded PLG-NP, and oral administration of isoniazid [13]; (f) Chemotherapeutic efficacy of drug-loaded PLG-NP nebulized to guinea pigs [13]; (g) Lung section of mouse from the non-treatment group (I), treated with doxorubicin solution intravenously (II), non-effervescent doxorubicin nanoparticle powder (III) and effervescent doxorubicin nanoparticle powder (IV) [14]; (h) Percent animal survival versus time [14].